Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting

126-week results from RESTORE follow-up study (REMAIN) to highlight the extended efficacy and safety of Nanoscope's MCO-010 optogenetic therapy for Retinitis Pigmentosa

DALLAS, July 28, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from retinal degenerative diseases, announced that its multi-characteristic opsin (MCO) gene therapy platform will be featured in a presentation by Dr. David S. Liao at the 2025 American Society of Retina Specialists Annual Scientific Meeting, taking place July 30-August 2, 2025 at the Long Beach Convention Center in Long Beach, California. 

Dr. Liao will present 126-week data on the strong efficacy and safety profile of MCO-010 in treating retinitis pigmentosa (RP) patients via a one time, in-office intravitreal injection without the need for genetic testing. Nanoscope recently initiated a rolling submission of a Biologics License Application (BLA) to the FDA for MCO-010 for the treatment of severe vision loss due to RP. The data, from Nanoscope's RESTORE follow-up study (REMAIN), form the backbone of Nanoscope's BLA rolling submission. 

Details for the presentation are as follows:

"We are excited to have this 126-week data presented at ASRS, especially with our recent BLA announcement," said Dr. Samuel Barone, Chief Medical Officer for Nanoscope.  "This will be a great opportunity for the ASRS community to discuss our data and its potential impact on RP patients."

For more information on MCO-010 and Nanoscope Therapeutics visit: www.nanostherapeutics.com.

About Nanoscope Therapeutics
Nanoscope Therapeutics is developing gene-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (RP) (NCT04945772), a rolling BLA submission to the FDA has been initiated. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD. Preclinical programs include Leber congenital amaurosis (LCA), in IND-enabling studies, as well as an IND-ready asset for geographic atrophy (GA). 

Contact:
Nanoscope Therapeutics
(817) 857-1186
[email protected] 

SOURCE Nanoscope Therapeutics